Meldonium Olpha (Meldonium Dihydrate)

Meldonium inhibits the enzyme γ‑butyrobetaine hydroxylase, decreasing L‑carnitine synthesis. This limits fatty‑acid entry into mitochondria, shifting heart muscle energy production toward glucose oxidation, which uses oxygen more efficiently and helps protect the myocardium during ischemic episodes.

The appropriate dose of Meldonium Olpha is determined by the prescribing clinician based on the patient’s clinical condition, severity of disease, and response to therapy. Specific dosing regimens are not disclosed publicly and should follow the prescriber’s instructions.

Safety data for Meldonium during pregnancy and lactation are limited. It should be avoided unless the potential therapeutic benefit justifies the possible risk to the fetus or infant. Clinicians must weigh risks carefully and discuss them with the patient.

To order Meldonium Olpha, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Meldonium’s primary alternative in the anti‑ischemic class is trimetazidine, which also shifts myocardial metabolism toward glucose utilization. Unlike trimetazidine, Meldonium directly reduces carnitine synthesis, offering a distinct metabolic pathway. Clinical choice depends on patient tolerance, specific cardiac profile, and physician preference.

Meldonium Olpha must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, should not be frozen, and must be gently inverted if mixing is required. Follow standard aseptic techniques when preparing for intravenous administration.

Meldonium Olpha is administered as an intravenous injection. The solution is drawn into a sterile syringe and infused over the period recommended by the treating physician, typically as a slow push or short infusion, depending on the clinical protocol.

Serious adverse reactions associated with Meldonium include hypotension, arrhythmia, severe allergic responses such as anaphylaxis, hepatotoxicity indicated by elevated liver enzymes, and severe injection‑site complications like necrosis or infection. Patients should be monitored closely for these events.

Meldonium is contraindicated in patients with known hypersensitivity to Meldonium or any excipients in the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled hypotension, or those receiving multiple potent antihypertensive agents. Pregnant or breastfeeding women should avoid use unless absolutely necessary.